In NSCLC, the MET overexpression detected by IHC has usually been associated with MET-GCNG/GA, though MET exon 14 skipping mutations have also been described more recently as alternative and mutually exclusive mechanism of MET-receptor overexpression and activation that can be targeted by MET inhibitors [2,3,5]. The gene discussed is MET; the disease is non-small cell lung carcinoma.